MedPath

Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

Recruiting
Conditions
Colorectal Cancer
Interventions
Other: Observation
Registration Number
NCT05234177
Lead Sponsor
Tempus AI
Brief Summary

The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
300
Inclusion Criteria
  • Known or suspected colorectal adenocarcinoma (Stage I to IVA disease)
  • Planning to undergo or has undergone a surgical resection for suspected adenocarcinoma of the colon or rectum with curative intent.
  • 18 years old or older
  • Willing and able to provide informed consent
  • Willing to have additional blood samples collected during routine surveillance visits
Exclusion Criteria
  • Not willing to have additional blood samples collected
  • Pathology that is not consistent with colorectal adenocarcinoma

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Participants with stage I-IV colorectal cancer (CRC)ObservationThis protocol will include participants with stage I-IV CRC who are scheduled to undergo or have undergone a surgical resection with curative intent.
Primary Outcome Measures
NameTimeMethod
Recurrence-Free Survival2 years

Recurrence-Free Survival as assessed by standard radiographic imaging, measured from the day of completion of definitive treatment to first radiographic recurrence or death

Secondary Outcome Measures
NameTimeMethod
Sensitivity2 years

Sensitivity defined as the proportion of participants who develop recurrence who have ctDNA detected.

Positive Predictive Value2 years

Positive predictive value (PPV) defined as the proportion of participants who have ctDNA detected who recur.

Specificity2 years

Specificity defined as the proportion of participants who do not develop recurrence who do not have ctDNA detected.

Trial Locations

Locations (40)

Mercy Clinic Oncology - Fort Smith

🇺🇸

Fort Smith, Arkansas, United States

MemorialCare

🇺🇸

Fountain Valley, California, United States

The Center for Cancer and Blood Disorders

🇺🇸

Bethesda, Maryland, United States

Mercy Clinic Oncology and Hematology - Joplin

🇺🇸

Joplin, Missouri, United States

Washington University School of Medicine

🇺🇸

Saint Louis, Missouri, United States

Mercy Clinic Oncology and Hematology - Sindelar Cancer Center

🇺🇸

Saint Louis, Missouri, United States

Mercy Clinic Oncology and Hematology - David C. Pratt Cancer Center

🇺🇸

Saint Louis, Missouri, United States

Mercy Clinic Cancer and Hematology - Chub O'Reilly Cancer Center

🇺🇸

Springfield, Missouri, United States

Nebraska Cancer Specialists

🇺🇸

Omaha, Nebraska, United States

Southeastern Medical Oncology Center

🇺🇸

Goldsboro, North Carolina, United States

Aultman Hospital

🇺🇸

Canton, Ohio, United States

TriHealth Cancer Institute

🇺🇸

Cincinnati, Ohio, United States

Ohio State University

🇺🇸

Columbus, Ohio, United States

OhioHealth Research Institute

🇺🇸

Columbus, Ohio, United States

Toledo Clinic Cancer Center

🇺🇸

Toledo, Ohio, United States

Mercy Clinic Oncology and Hematology - Coletta

🇺🇸

Oklahoma City, Oklahoma, United States

Cancer Care Associates of York

🇺🇸

York, Pennsylvania, United States

Utah Cancer Specialists

🇺🇸

Salt Lake City, Utah, United States

University of Washington / Fred Hutchinson Cancer Center

🇺🇸

Seattle, Washington, United States

ThedaCare Regional Cancer Center

🇺🇸

Appleton, Wisconsin, United States

Mercy Clinic Oncology - Fort Smith

🇺🇸

Fort Smith, Arkansas, United States

MemorialCare

🇺🇸

Fountain Valley, California, United States

The Center for Cancer and Blood Disorders

🇺🇸

Bethesda, Maryland, United States

Mercy Clinic Oncology and Hematology - Joplin

🇺🇸

Joplin, Missouri, United States

Washington University School of Medicine

🇺🇸

Saint Louis, Missouri, United States

Mercy Clinic Oncology and Hematology - Sindelar Cancer Center

🇺🇸

Saint Louis, Missouri, United States

Mercy Clinic Oncology and Hematology - David C. Pratt Cancer Center

🇺🇸

Saint Louis, Missouri, United States

Mercy Clinic Cancer and Hematology - Chub O'Reilly Cancer Center

🇺🇸

Springfield, Missouri, United States

Nebraska Cancer Specialists

🇺🇸

Omaha, Nebraska, United States

Southeastern Medical Oncology Center

🇺🇸

Goldsboro, North Carolina, United States

Aultman Hospital

🇺🇸

Canton, Ohio, United States

TriHealth Cancer Institute

🇺🇸

Cincinnati, Ohio, United States

Ohio State University

🇺🇸

Columbus, Ohio, United States

OhioHealth Research Institute

🇺🇸

Columbus, Ohio, United States

Toledo Clinic Cancer Center

🇺🇸

Toledo, Ohio, United States

Mercy Clinic Oncology and Hematology - Coletta

🇺🇸

Oklahoma City, Oklahoma, United States

Cancer Care Associates of York

🇺🇸

York, Pennsylvania, United States

Utah Cancer Specialists

🇺🇸

Salt Lake City, Utah, United States

University of Washington / Fred Hutchinson Cancer Center

🇺🇸

Seattle, Washington, United States

ThedaCare Regional Cancer Center

🇺🇸

Appleton, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath